
Sign up to save your podcasts
Or


Venrock partner Andrew Gottesdiener speaks with Jigar Raythatha, former CEO of Constellation Pharmaceuticals, about lessons learned from his time at Constellation. As Constellation has evolved from an early-stage company to being acquired by MorphoSys, Raythatha dives into its many life-cycles, his heavy involvement in the recruitment process, and the decision to conduct a PIPE financing. Raythatha also shares the characteristics to look for in an investor syndicate and the challenges of scaling a public company.
By Venrock, a venture capital firm4.8
6262 ratings
Venrock partner Andrew Gottesdiener speaks with Jigar Raythatha, former CEO of Constellation Pharmaceuticals, about lessons learned from his time at Constellation. As Constellation has evolved from an early-stage company to being acquired by MorphoSys, Raythatha dives into its many life-cycles, his heavy involvement in the recruitment process, and the decision to conduct a PIPE financing. Raythatha also shares the characteristics to look for in an investor syndicate and the challenges of scaling a public company.

1,296 Listeners

2,672 Listeners

2,461 Listeners

1,105 Listeners

341 Listeners

337 Listeners

394 Listeners

5,610 Listeners

10,254 Listeners

34 Listeners

551 Listeners

21 Listeners

300 Listeners

475 Listeners

1,480 Listeners